Abstract: Disclosed herein are methods and compositions related to the treatment, prevention, and/or amelioration of cancer in a subject in need thereof.

Abstract: Provided are multi-arm polymer conjugates of Toll-Like Receptor (“TLR”) agonists such as TLR 7/8 agonists, as well as related compositions, and methods of making and using such conjugates. Exemplary conjugates are encompassed by Formula I: or a pharmaceutically acceptable salt form thereof, where R, taken together with each Q, is a residue of a polyol, polythiol, or polyamine bearing from 3 to about 50 hydroxyl, thiol, or amino groups; each Q is a linker selected from oxygen, sulfur and —NH; each POLY is independently a water-soluble, non-peptidic polymer; each Xr is independently a linkage-containing spacer moiety; q is a positive integer from 3 to about 50; and each TLR 7/8 AG is a Toll-like receptor 7/8 agonist. Also provided is a method of administering to a patient having cancer (a) an IL-2R?-activating amount of a long-acting, IL-2R?-selective agonist; and (b) a Toll-like receptor agonist such as a conjugate as described above, as well as related compositions, kits and methods.

Abstract: The disclosure relates to a data processing method, apparatus, readable medium, computing device, computer program product, and computer program. The method is implemented at a computing device. A virtual machine is executed in the computing device. The method includes: in response to a target virtual device receiving a data read/write request, writing, into a shared memory, target data comprised in the data read/write request, the target virtual device being a virtual device in the virtual machine; sending an interrupt instruction to a target physical processor in the computing device through a pass-through register corresponding to the target virtual device, the interrupt instruction being used by the target physical processor to acquire the target data from the shared memory according to the interrupt instruction, and inform, based on the target data, a corresponding back-end service program to process the data read/write request.

Abstract: An array substrate and a method for manufacturing an array substrate. The array substrate includes a display region and a non-display region. The non-display region is located at least on one side of the display region. The array substrate also includes a substrate, a driver circuit layer, and a pad layer. The substrate includes a first surface and a second surface that are disposed opposite to each other and a side surface connected to the first surface and the second surface. The driver circuit layer is disposed on the first surface and includes at least one signal layer. The at least one signal layer extends from the display region to the non-display region. The pad layer is disposed in the display region and includes at least one pad. The at least one pad is electrically connected to the at least one signal layer.

Abstract: The disclosure relates to a method, non-transitory computer-readable storage medium, and device of virtual machine resource allocation. The method includes: when virtual machines are created in a physical machine, allocating corresponding bare machine devices to the virtual machine, the bare machine devices being obtained by segmenting physical resources of the physical machine, and the virtual machine being in one-to-one correspondence with the bare machine devices; configuring the operation mode of the bare machine devices into a non-root mode; and switching the operation mode of a CPU of the physical machine to the non-root mode so as to start the virtual machines in the bare machine devices.

Abstract: Provided is a method of administering to a patient having cancer: (a) a 4-1BB agonist; (b) an IL-2R?-activating amount of a long-acting, IL-2R?-selective agonist; and/or (c) a toll-like receptor agonist, as well as related compositions, kits and compositions.

Abstract: The present disclosure relates generally to the fields of oncology, virology and immunotherapy. It concerns poxviruses, specifically the highly attenuated modified vaccinia virus Ankara (MVA), and a recombinant modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MVA?E3L), each further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L) or GM-CSF. The disclosure relates to use of the foregoing recombinant viruses as cancer immunotherapeutic agents. The foregoing recombinant poxviruses can also be used in combination with immune checkpoint blockade therapy.

Abstract: Disclosed herein are methods in the field of cancer immunotherapy that involve the treatment of a subject having cancer by administering to the subject a toll-like receptor 7/8 (TLR7/8) agonist in combination with a long-acting IL-2R?-biased agonist and a programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) axis inhibitor, and related compositions, dosage forms, and kits.

Abstract: The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of poxviruses, specifically the replication competent attenuated vaccinia virus with deletion of thymidine kinase (VC-TK?) with and without the expression of human Flt3L or GM-CSF as oncolytic and immunotherapy. The foregoing poxviruses can also be used in combination with immune checkpoint blocking agents. The foregoing poxviruses can also be inactivated via Heat or UV-treatment and the inactivated virus can be used as immunotherapy either alone or in combination with immune checkpoint blocking agents.

Abstract: In an embodiment, a memory controller in an integrated circuit may generate refreshes for one or more DRAMs coupled to the integrated circuit according to a refresh rate. The integrated circuit may include one or more temperature sensors. A rate of change of the temperature may be determined from the temperature sensors. If the rate is greater than a threshold, the memory controller may generate refreshes according to a refresh rate specified by the DRAMs. If the rate is less than the threshold, the memory controller may generate refreshes at a reduced refresh rate.

Abstract: Disclosed are an offline uninterruptible power source and a control method therefor.

Abstract: Disclosed herein are methods and compositions related to the treatment, prevention, and/or amelioration of cancer in a subject in need thereof. In particular aspects, the present technology relates to the use of poxviruses, including a recombinant modified vaccinia Ankara (MVA) virus or vaccinia virus with deletion of vaccinia host-range factor C7 (MVA?C7L and VACV?C7L, respectively), alone or in combination with immune checkpoint blocking agents, as an oncolytic and immunotherapeutic composition. In some embodiments, the technology of the present disclosure relates to a MVA?C7L or VACV?C7L virus further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L).

Abstract: Throttling circuitry may throttle the backlight reconstruction via backlight reconstruction and compensation circuitry in a display pipeline when power may be limited. This throttling of the display pipeline may limit a number of cycles that may be used for performing backlight reconstruction and compensation.

Abstract: Provided are multi-arm polymer conjugates of Toll-Like Receptor (“TLR”) agonists such as TLR 7/8 agonists, as well as related compositions, and methods of making and using such conjugates. Exemplary conjugates are encompassed by Formula I: RQ-POLY-Xr-TLR7/8 AG)q??Formula I or a pharmaceutically acceptable salt form thereof, where R, taken together with each Q, is a residue of a polyol, polythiol, or polyamine bearing from 3 to about 50 hydroxyl, thiol, or amino groups; each Q is a linker selected from oxygen, sulfur and —NH; each POLY is independently a water-soluble, non-peptidic polymer; each Xr is independently a linkage-containing spacer moiety; q is a positive integer from 3 to about 50; and each TLR 7/8 AG is a Toll-like receptor 7/8 agonist.

Abstract: In an embodiment, a memory controller in an integrated circuit may generate refreshes for one or more DRAMs coupled to the integrated circuit according to a refresh rate. The integrated circuit may include one or more temperature sensors. A rate of change of the temperature may be determined from the temperature sensors. If the rate is greater than a threshold, the memory controller may generate refreshes according to a refresh rate specified by the DRAMs. If the rate is less than the threshold, the memory controller may generate refreshes at a reduced refresh rate.

Abstract: The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of poxviruses, specifically the replication competent attenuated vaccinia virus with deletion of thymidine kinase (VC-TK?) with and without the expression of human Flt3L or GM-CSF as oncolytic and immunotherapy. The foregoing poxviruses can also be used in combination with immune checkpoint blocking agents. The foregoing poxviruses can also be inactivated via Heat or UV-treatment and the inactivated virus can be used as immunotherapy either alone or in combination with immune checkpoint blocking agents.

Abstract: Provided are multi-arm polymer conjugates of Toll-Like Receptor (“TLR”) agonists such as TLR 7/8 agonists, as well as related compositions, and methods of making and using such conjugates. Exemplary conjugates are encompassed by Formula I: (I) or a pharmaceutically acceptable salt form thereof, where R, taken together with each Q, is a residue of a polyol, polythiol, or polyamine bearing from 3 to about 50 hydroxyl, thiol, or amino groups; each Q is a linker selected from oxygen, sulfur and —NH; each POLY is independently a water-soluble, non-peptidic polymer; each Xr is independently a linkage-containing spacer moiety; q is a positive integer from 3 to about 50; and each TLR 7/8 AG is a Toll-like receptor 7/8 agonist. Also provided is a method of administering to a patient having cancer (a) an IL-2R?-activating amount of a long-acting, IL-2R?-selective agonist; and (b) a Toll-like receptor agonist such as a conjugate as described above, as well as related compositions, kits and methods.

Abstract: Throttling circuitry may throttle the backlight reconstruction via backlight reconstruction and compensation circuitry in a display pipeline when power may be limited. This throttling of the display pipeline may limit a number of cycles that may be used for performing backlight reconstruction and compensation.

Abstract: A process running method and apparatus are provided. The method includes: receiving a process startup request; executing an executable file of a target process in a kernel based on the process startup request, to obtain first running function data that supports running of the target process in the kernel; migrating the first running function data to a functional safety partition to obtain second running function data, where the functional safety partition and the kernel are located at a same privilege layer; and running the target process in the functional safety partition based on the second running function data. According to the present disclosure, both the functional safety partition and the kernel are located at a kernel layer. In this way, during process running, a service at the kernel layer can be called without switching from a user layer to the kernel layer.

Abstract: Throttling circuitry may throttle the backlight reconstruction via backlight reconstruction and compensation circuitry in a display pipeline when power may be limited. This throttling of the display pipeline may limit a number of cycles that may be used for performing backlight reconstruction and compensation.